Shasqi

Our team is moving on up! 👀 Big shout out to Travis, Sangeetha and Jesse. 👏 Smart, committed, collaborative and friendly—you're exactly the kind of people we love working with. Thank you for all you contribute to bringing Shasqi's mission to life!

We're hiring! What gets you excited to go to work every day? Our team is driven by the opportunity to create a new future in targeted therapy by unleashing cancer drugs only at the tumor. If you thrive in a collaborative environment and want to help shape something transformative from the ground up, check out our job openings: ⭐️ Director, Clinical Operations ⭐️ Executive Director of Protein Engineering and Chemistry ⭐️ Principal Scientist, ADME/PK ⭐️ Principal Scientist, Toxicology & Pharmacology Postings: https://lnkd.in/gVd5yXjY. We are focusing on candidates whose experience matches the role requirements. If your background is closely aligned and you’re interested in learning more, please send a brief note with your experience and a LinkedIn profile or CV to the careers email on our website (link to page in comments). Sangeetha, Nathan, Sadie and Travis: Thank you for sharing what motivates you!

Two parts. One click. Senior Director of In Vivo Biology Sangeetha Srinivasan, Ph.D. explains what CAPAC is, how it differs from ADCs, and what this novel technology means for the future of cancer therapy. 💥 

A big congratulations to Shasqi's Executive Assistant to the CEO Lindsay Daum, MBA, on her four-year anniversary.  Lindsay is the glue that holds Shasqi together. To borrow a train metaphor, she not only keeps the trains running on time, but she builds the schedule, maintains the engines, and makes sure no one misses their connection! Lindsay is a powerful, strategic partner who boosts our effectiveness, brings clarity to complexity, and helps us see the big picture. We truly couldn't do it without her--and we wouldn't want to.  👇 Lindsay shares what she most enjoys about working at Shasqi below.

We're hiring! What makes Shasqi special is the combination of *really cool* science that genuinely pushes boundaries and a smart team, who are deeply motivated by the mission and have fun together while working hard. We’re also at a critical inflection point, preparing to enter the clinic in 2027, which creates an opportunity to help us shape a program and be a part of building something meaningful from the ground up. Job openings are: --Director, Clinical Operations --Executive Director of Protein Engineering and Chemistry --Principal Scientist, ADME/PK --Principal Scientist, Toxicology & Pharmacology Job postings 👉: https://lnkd.in/gVd5yXjY If your background is closely aligned and you’re interested in learning more, please send a brief note with your experience and a LinkedIn profile or CV to our careers email on our website: https://lnkd.in/g7UYZbxQ. 

It's time to double click! Here's the latest round up of what’s been inspiring us across science, biotech and health. We are: 🧬 1. Impressed by: 'Smart' drugs!? Scientists have built a programmable system from synthetic DNA that only activates when it detects a specific combination of tumor markers, sparing healthy tissue. It can also deliver multiple drugs at once, potentially overcoming resistance. ~ Michael Zakharian 🔬 2. Intrigued by: Brain tumors are among the most difficult cancers to treat because of the therapy-blocking blood-brain barrier. This Phase 1 study featured in Neuro-Oncology uses a new technique to deliver antibody-based radiotherapy directly to the tumor. And it's the first-ever human use of a ¹²⁴I radiopharmaceutical as a theranostic agent, using one compound for both imaging and treatment. Early but interesting science! ~ Stefanie Wagner, MSc 🫁 3. Excited by: Small cell lung cancer is one of the most aggressive and lethal solid tumors. The potential of this clinical collab between Zai Lab and Amgen to improve outcomes for patients with small cell lung cancer with DLL3-directed therapies is exciting. ~ George Coricor, Ph.D.  Links to the articles in the comments!

Between presenting our own work, I carved out time to explore the poster halls at #AACR2026. Fascinating to see the range of targets being pursued and the diversity of payloads being explored — the field is clearly hungry for better solutions. Which only reinforces why we're so excited about what we're building at Shasqi. The need for a wider therapeutic window in targeted cancer therapy has never been more clear.

What a day at #AACR2026! 🎉 Our poster drew a fantastic crowd — so many thoughtful questions and genuine curiosity from researchers across the field. Big thanks to Michael Zakharian, Travis Biechele (CSO), and José M. Mejía Oneto (CEO) for jumping in alongside me to make sure we could keep up with the energy in the room. #Oncology #Biotech #AACR

Come say hello today at #AACR26! One of the things we love about conferences is seeing our team in action and the excitement among peers around the science we're leading at Shasqi. Stop by before 5 pm PDT to hear about our lead program and meet Founder & CEO José M. Mejía Oneto, MD, PhD; Chief Scientific Officer Travis Biechele, PhD; Principal Scientist Masa Aleckovic, PhD; and Senior Scientist / IP Portfolio Manager Michael Zakharian: Poster Section 18, Board 16, Poster 446. Poster abstract linked in the comments 👇

The team have arrived at #AACR26! Yesterday, our CSO Travis Biechele presented at the AACR Oncology Industry Partnering Event, sharing more info on our Click Activated Protodrugs Against Cancer technology and how using this approach leads to superior efficacy over ADCs. 💪 Coming up on Sunday, 2-5 pm PT, Masa Aleckovic, PhD will be sharing data on our lead program: Poster Section 18, Board 16, Poster 446. Stop by and say hello!